ich q6b - implications for developers of … q6b - implications for developers of biopharmaceuticals...
TRANSCRIPT
![Page 1: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/1.jpg)
ICH Q6B - implications for developersof biopharmaceuticals
March 2012
Originally presented by GxPi on23 November 2010
![Page 2: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/2.jpg)
© GxPi 2012 2
Presentation Overview
“A strategic overview of the considerations that any organisation should apply to its analytical test methodologies and how it is addressing the ICH guidelines. What are the risks that need to be managed? Where does the focus of effort need to be? What resources can be used to achieve the results in a smart, efficient manner? What key measures of success need to be built into the approach – time, cost, retained knowledge? The talk will also look at how the requirements to meet the guidelines evolve with the product during the development lifecycle.”
![Page 3: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/3.jpg)
© GxPi 2012 3
GxPi Overview
“We simplify complex process and technology environments to deliver our customers’
compliance and quality goals in their regulatory framework.
We achieve this through a combination of Services and Products that transfer our expertise
to our customers”.
![Page 4: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/4.jpg)
© GxPi 2012 4
ICH Guidelines
“The purpose is to make recommendationson ways to achieve greater harmonisation in the interpretation and application of technical guidelines and requirements for product registration in order to reduce or obviate the need to duplicate the testing carried out during the research and development of new medicines.”
Source: ICH Website (www.ich.org)
![Page 5: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/5.jpg)
© GxPi 2012 5
ICH Q6B
• Uniform set of international specifications for
biotechnological and biological products to support
new marketing applications
• Used to define the quality of the biological
product, not full characterisation
• To be an integral part of your GMP operations
for the production of the material
![Page 6: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/6.jpg)
© GxPi 2012 6
ICH Q6B – Managing risk
What are the real risks?
• Unable to generate standards• Unacceptable variance in material
specification and quality
Which results in.......
• Repeat work required• Additional support work required
![Page 7: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/7.jpg)
© GxPi 2012 7
ICH Q6B – Managing risk
• DELAY
• COST
• LOSS OF PROFIT
![Page 8: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/8.jpg)
© GxPi 2012 8
ICH Q6B – Development Cycle
• What are the significant differences in the manufacturing techniques, quality and specification of material needed for pre-clinical and clinical phases?
• NONE!
![Page 9: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/9.jpg)
© GxPi 2012 9
ICH Q6B – Prioritisation of effort
• Once you have isolated your material......
• The principles of GMP should be applied at all stages of the development:
• Personnel• Materials• Procedures• Operations• Management
![Page 10: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/10.jpg)
© GxPi 2012 10
ICH Q6B – People
• People - The biggest impact upon the quality, consistency, repeatability and continuing improvement of the product and associated testing
• GMP culture
• GMP knowledge and experience
• GMP training and rules
![Page 11: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/11.jpg)
© GxPi 2012 11
ICH Q6B – Materials
• Materials – There is little point in investing heavily
in science and techniques if starting materials are of
inferior quality....
• Proven, reliable sources of materials
• Appropriate specifications and technical agreements
• Audit, test and records
• GMP!
![Page 12: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/12.jpg)
© GxPi 2012 12
ICH Q6B – Procedures
• Procedure – The need to translate the processes of
the lead development scientists into a set of GMP
instructions....
• Repeatable?
• Transferable?
• Scalable?
• A simple process or technique is no less important to
the quality of the end product
![Page 13: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/13.jpg)
© GxPi 2012 13
ICH Q6B – Operations
• Operations – The operation for development and
manufacture, specification and testing of the material must be
run as a GMP process, irrespective of size
• Equipment / facility – validated and recorded?
• Methods – validated and documented?
• Batch records to support all material?
• CAPA?
• Change Control?
![Page 14: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/14.jpg)
© GxPi 2012 14
ICH Q6B – Development
• Development – Providing a consistent and reliable foundation
for a new Substance / Product that enables an effective and
efficient development program
• Production / extraction process?
• Stability of material (how quickly will the standard denature /
degrade?)
• Outsource to experts where appropriate
• Don’t jump in too soon!
![Page 15: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/15.jpg)
© GxPi 2012 15
ICH Q6B – Development (2)
• Development – How do we standardise a novel substance or product?
• As many batches / runs as possible
• Ensure consistency in materials, processes, controls and results
• GMP!
![Page 16: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/16.jpg)
© GxPi 2012 16
ICH Q6B – Spec. development
• Good News!
• Advances in analytical technology (e.g. Mass Spec. -characterise proteins, quantify variant form) – USE THEM!
• Biological activity – may take time to identify a precise method (e.g. enzyme or binding)
• Contaminants – Host Cell Protein (HCP), host DNA, endotoxin....
• Drug product – what is the potential impact of the presentation (e.g. Syringe material)?
![Page 17: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/17.jpg)
© GxPi 2012 17
ICH Q6B – Spec. Development
So where to best focus your efforts?
• Transfer of information – Development scientists to Analytical team
• Use partners and specialist service providers for testing methods. It is their day job
• Working on the consistency, repeatability and quality of the product
![Page 18: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/18.jpg)
© GxPi 2012 18
ICH Q6B – Management
• The biggest risks are often the transition stages
between phases.....
![Page 19: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/19.jpg)
© GxPi 2012 19
ICH Q6B – Management
• Management – There must be ownership and understanding of the entire test development process from concept to completion
• Total Quality Management – the smallest error or oversight can invalidate the test method or compromise product safety, quality or efficacy
• This is a project and requires a competent Project Manager to be assigned
• Think like a production operation, irrespective of size of the operation
![Page 20: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/20.jpg)
© GxPi 2012 20
ICH Q6B – Quality
• You can’t test quality into the product at the end of
the process......
![Page 21: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/21.jpg)
© GxPi 2012 21
ICH Q6B – Conclusions
• GMP processes must be applied from early stages of the product development / test method development program
• Reduce risk by using quality materials, consistency in the starting material process and having validated methods from the start
• The simple routine tasks are as important as the complicated, exciting ones.
![Page 22: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/22.jpg)
© GxPi 2012 22
References
• GxPi website: www.gxpi.com
• Contact name: Mark Stevens
• Email: [email protected]
• Telephone: +44(0)115 924 8475
• Other useful websites:
• ICH: www.ich.org
• BIA: www.bioindustry.org
![Page 23: ICH Q6B - implications for developers of … Q6B - implications for developers of biopharmaceuticals March 2012 Originally presented by GxPi on 23 November 2010 © GxPi 2012 2 Presentation](https://reader034.vdocument.in/reader034/viewer/2022051600/5aab3a1f7f8b9a2b4c8bbbcb/html5/thumbnails/23.jpg)
© GxPi 2012 23
Products and Services that are
Simply Compliant